Gilead Issues A Voluntary Recall Of One Lot Of Vistide® (CIDOFOVIR INJECTION) Due To Presence Of Particulate Matter

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Gilead Issues A Voluntary Recall Of One Lot Of Vistide® (CIDOFOVIR INJECTION) Due To Presence Of Particulate Matter

02/15/2013 09:25 PM EST

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is voluntarily recalling lot B120217A of Vistide® (cidofovir injection) to the user level due to the presence of particulate matter found in some vials of this lot.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420